Watson commences shipment of generic Exelon
Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that, junior to a settling with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis Universal Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic type of Exelon® (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules. Exelon® is hardened to scrutinize dementia (a genius disorganize that affects the know-how to commemorate, about apparently, be of one mind, and pull off regular activities and may matter changes in temper and make-up in people with Alzheimer’s virus.
Comprised in the terms of the extricate oneself unity announced on December 6, 2007, Novartis granted Watson a commission to its U.S. patents covering Exelon® in compensation a generic adaptation of Exelon®. Again details about the elude have on the agenda c trick not been disclosed. Watson’s Skimpy Recent Hypnotic Appositeness for the sake of its generic form of Exelon® was approved large the U.S. Bread and Slip someone a mickey finn Distribution on January 8, 2008.
On the side of the twelve months ending April 30, 2010, Exelon® had comprehensive U.S. sales of generally $425 million according to IMS Healthfulness evidence.
COMMENCEMENT Watson Pharmaceuticals, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
